Product logins

Find logins to all Clarivate products below.


Methicillin-Resistant Staphylococcus Aureus Infections – Epidemiology – Europe Data

Methicillin-Resistant Staphylococcus aureus Epidemiology

DRG Epidemiology’s coverage of methicillin-resistant staphylococcus aureus comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the incidence of methicillin-resistant staphylococcus aureus for each country, as well as annualized case counts projected to the national population.

DRG Epidemiology’s methicillin-resistant staphylococcus aureus forecast will answer the following questions:

How will changes in the levels of exposure to known risk or protective factors affect the number of methicillin-resistant staphylococcus aureus events per year?

Of all people diagnosed with methicillin-resistant staphylococcus aureus, how many in each country across the major mature pharmaceutical markets are drug-treated?

How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of methicillin-resistant staphylococcus aureus over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following methicillin-resistant staphylococcus aureus patient populations:

Diagnosed MRSA Events by Treatment

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – BSI

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – cIAI

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – cSSSI

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – HAP

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – HCAP

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – Nosocomial Pneumonia

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events – SSI

… and more (details available on request).

Note: coverage may vary by country and region.

Related Market Assessment Reports

Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Psoriatic Arthritis – Unmet Need – Unmet Need – Psoriatic Arthritis (US/EU)
The psoriatic arthritis (PsA) therapy market is on a growth trajectory, fueled by the disease’s increasing prevalence, innovative treatment options, and heightened patient awareness. TNF-alpha…
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…